- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX
- Radiation · Drug
- Lead sponsor
- Gulam Manji
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 3,335
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Polyneuropathy
- Interventions
- Eptinezumab, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 23
- States / cities
- Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK1292263, GSK1292263 matching placebo, Sitagliptin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Miami, Florida
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
- Conditions
- GHD
- Interventions
- GenSci004, Genotropin
- Drug
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Disability Physical, Impairment, Cognitive, Caregiver Burden, Quality of Life, Depression
- Interventions
- CAPABLE Family - Open Label Pilot, CAPABLE Family - Randomized Control Trial
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alport Syndrome
- Interventions
- lademirsen (SAR339375), Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
- Conditions
- Social Anxiety Disorder
- Interventions
- Fasedienol Nasal Spray, Placebo Nasal Spray
- Drug
- Lead sponsor
- VistaGen Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more
- Conditions
- Respiratory Distress Syndrome (RDS)
- Interventions
- LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
- Combination Product · Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 30 Minutes to 24 Hours
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
- Conditions
- Asthma, Vitamin D Deficiency
- Interventions
- Vitamin D2 + vitamin D3, Vitamin D3
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- dimethyl fumarate, Interferon β-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- HIV-1-infection
- Interventions
- Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- GeneSight Psychotropic
- Genetic
- Lead sponsor
- Assurex Health Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
- Conditions
- Hepatitis C
- Interventions
- GSK2336805
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- Lentigo Maligna, Melanoma In Situ
- Interventions
- H&E, IHC MART-1, IF MART-1, IF cocktail
- Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Major Depressive Disorder
- Interventions
- NBI-1065845, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Oceanside, California • Orange, California • San Jose, California + 21 more
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, Peg-IFN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
- Conditions
- Chronic Obstructive Pulmonary Disease - COPD
- Interventions
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 20
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
- Conditions
- Dry Eye, Dry Eye, Evaporative, Dry Eye Disease, Evaporative Dry Eye, Evaporative Dry Eye Disease, Kerato Conjunctivitis Sicca
- Interventions
- Miebo
- Drug
- Lead sponsor
- Gordon Schanzlin New Vision
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Coronado, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Refractive Error - Myopia Bilateral
- Interventions
- Deseyne Daily Disposable Contact Lens (Test Device)
- Device
- Lead sponsor
- Bruno Vision Care
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Longwood, Florida • Pittsburg, Kansas • Warwick, Rhode Island
- Conditions
- Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
- Interventions
- Calcium Chloride, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
- Interventions
- Placebo Matching Mitapivat, Mitapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more